Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

Aneel Paulus, MD, Prachi Jani, MD, Salman Ahmed, MD, Sonikpreet Aulakh, MD, Alak Manna, PhD, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Zakir Husain, M.Tech, Ansu Kumar, M.Sc., Pallavi Kumari, M.Sc., Anuj Tyagi, M.Sc., Taimur Sher, MD, Rami Manochakian, MD, Vivek Roy, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2018-99-119574

Published: 2018

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice

David Askew, Tej K. Pareek, Saada Eid, Sudipto Ganguly, Megan Tyler, Alex Y. Huang, John J. Letterio, Kenneth R. Cooke

Blood (2017) 129 (2): 246–256.

https://doi.org/10.1182/blood-2016-05-702738

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, MD PhD, Lydia Scarfo, Kumudu Pathiraja, Martha Derosier, Karen Small, Nigel Patton

Blood (2015) 126 (23): 4171.

https://doi.org/10.1182/blood.V126.23.4171.4171

Published: 2015

Journal Articles

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Shaji K. Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey Zonder, Natalie Callander, Rafael Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

Blood (2015) 125 (3): 443–448.

https://doi.org/10.1182/blood-2014-05-573741

Published: 2015

Journal Articles

Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

David Alagpulinsa, BPham, Srinivas Ayyadevara, PhD, Shmuel Yaccoby, PhD, Robert shmookler Reis, DPhil

Blood (2014) 124 (21): 479.

https://doi.org/10.1182/blood.V124.21.479.479

Published: 2014

Journal Articles

The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes

Blood (2014) 124 (21): 705.

https://doi.org/10.1182/blood.V124.21.705.705

Published: 2014

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

Christian Rohde, PhD, Till Schoofs, Katja Hebestreit, Hans-Ulrich Klein, PhD, Anika Witten, PhD, Monika Stoll, PhD, Eva Lengfelder, MD, Wolf-Karsten Hofmann, MD, Peter Schlenke, PhD, Stefanie Göllner, PhD, Thomas Büchner, MD, Maria Cristina Sauerland, Steffen Koschmieder, MD, Wolfgang E. Berdel, Martin Dugas, MD, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 2436.

https://doi.org/10.1182/blood.V118.21.2436.2436

Published: 2011

Journal Articles

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Yuan Xiao Zhu, Rodger Tiedemann, Chang-Xin Shi, Holly Yin, Jessica E. Schmidt, Laura A. Bruins, Jonathan J. Keats, Esteban Braggio, Chris Sereduk, Spyro Mousses, A. Keith Stewart

Blood (2011) 117 (14): 3847–3857.

https://doi.org/10.1182/blood-2010-08-304022

Published: 2011

Includes: Supplemental data

Journal Articles

Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease.

Jan Verner, PhD, Jitka Kabathova, Dr, Zbynek Zdrahal, Dr, Alexandra Tomancova, Jana Volejnikova, MD, Yvona Brychtova, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD

Blood (2010) 116 (21): 4549.

https://doi.org/10.1182/blood.V116.21.4549.4549

Published: 2010

Journal Articles

Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods

Brian Van Ness, Ph.D., Majda Haznadar, Ph.D., Gang Fang, Wen Wang, Vanja Paunic, Michael Steinbach, Vipin Kumar, Ph.D., Patrick Day, Johnson David, Gareth J Morgan, MD, PhD, Bart Barlogie, MD, PhD, Brian GM Durie, MD

Blood (2010) 116 (21): 2973.

https://doi.org/10.1182/blood.V116.21.2973.2973

Published: 2010

Journal Articles

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Blood (2010) 116 (7): 1025–1034.

https://doi.org/10.1182/blood-2009-12-257485

Published: 2010

Includes: Supplemental data

Journal Articles

Peripheral T-Cell Lymphoma. Molecular Heterogeneity Revealed by Integrative Genomic Analysis.

Magdalena Barbara Wozniak, Maria Socorro Rodriguez-Pinilla, Esperanza Martin, Francisco Javier Alves, Manuela Mollejo, Miguel A. Piris, MD

Blood (2009) 114 (22): 969.

https://doi.org/10.1182/blood.V114.22.969.969

Published: 2009

Journal Articles

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

Violetta Leshchenko, PhD, Pei-Yu Kuo, MS, Rita Shaknovich, MD, PhD, Tobias Gellen, Yvonne Remache, BS, Marc Weniger, PhD, K. Stephen Suh, PhD, Andre Goy, MD, Wyndham Wilson, MD, PhD, Ira Braunschweig, MD, Amit Verma, MD, Adrian Wiestner, MD, PhD, Ari Melnick, MD, Samir Parekh, MD

Blood (2009) 114 (22): 673.

https://doi.org/10.1182/blood.V114.22.673.673

Published: 2009

Journal Articles

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Yuan Xiao Zhu, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Chang-Xin Shi, PhD, Jessica Schmidt, BS, Laura Bruins, Jonathan J Keats, PhD, Holly Yin, PhD, Chris Sereduk, Spyro Mousses, PhD, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 602.

https://doi.org/10.1182/blood.V114.22.602.602

Published: 2009

Journal Articles

Roscovitine Prevents Alloreactive T Cell Expansion and TNF-a-Mediated Proinflammatory Gene Expression and Protects against GvHD.

Lequn Li, MD, PhD, Hui Wang, MD, PhD, Roderick Bronson, MD, Vassiliki Boussiotis, MD, PhD

Blood (2008) 112 (11): 2341.

https://doi.org/10.1182/blood.V112.11.2341.2341

Published: 2008

Journal Articles

Roscovitine Prevents TCR-Mediated T Cell Clonal Expansion In-Vitro and Protects Against GvHD In-Vivo.

Lequn Li, MD, PhD, Hui Wang, MD, PhD, Vassiliki A. Boussiotis, MD, PhD

Blood (2007) 110 (11): 318.

https://doi.org/10.1182/blood.V110.11.318.318

Published: 2007

Journal Articles

A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma.

Wee-Joo Chng, MD, Rafael Fonseca, MD

Blood (2006) 108 (11): 3388.

https://doi.org/10.1182/blood.V108.11.3388.3388

Published: 2006

NARROW

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease.

Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Peripheral T-Cell Lymphoma. Molecular Heterogeneity Revealed by Integrative Genomic Analysis.

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Roscovitine Prevents Alloreactive T Cell Expansion and TNF-a-Mediated Proinflammatory Gene Expression and Protects against GvHD.

Roscovitine Prevents TCR-Mediated T Cell Clonal Expansion In-Vitro and Protects Against GvHD In-Vivo.

A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only